Uveitis - Drug Pipeline Landscape, 2023

Uveitis - Drug Pipeline Landscape, 2023

Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based on which part of the uvea is affected they are anterior uveitis, intermediate uveitis, posterior uveitis, and pan uveitis.

Uveitis is caused by autoimmune diseases like AIDS, Ankylosing spondylitis, Behest's disease, Lupus and multiple sclerosis, psoriasis, and rheumatoid arthritis and sometimes due to infections. Uveitis may also cause due to cancers that affect the eye, like lymphoma.

Signs and symptoms of Uveitis include spots in the eye that look like tiny rods or chains of transparent bubbles floating around in the field of vision, eye pain and redness, vision problems, including blurred or cloudy vision, photophobia, an abnormal sensitivity to light, headaches.

The diagnosis of Uveitis is seeing white blood cells either in the anterior chamber or vitreous and other findings include bumps on the cornea, called keratic precipitates. If there is inflammation in the iris, patients may feel some pain when contracts of pupil due to light.

The most common treatment of Uveitis are eye drops containing anti-inflammatory agents, antibiotics or antiviral medication and steroids which are given in the form of oral or injection or surgical implant that provide small doses of steroids over time.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Uveitis treatment such as Brepocitinib, LY3009104, TRS01 and others. Key players involved in the development of therapies to treat Uveitis are ACELYRIN Inc, Eli Lilly and Company, Eyevensys, Oculis Pharma, Tarsier Pharma and others. Two drugs are under late-stage Phase III clinical trials and five drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Uveitis - Drug Pipeline Landscape, 2023 report provides an overview of the Uveitis pipeline drugs. This report covers detailed insights on Uveitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Uveitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.